In order to evaluate the potential of CXCL8 and CXCL1 as predictive biomarkers of OXA plus Curcumin treatment response, we analysed gene expression of both chemokines in a panel of 8 FFPE samples from explant cultures of CRC patients-derived liver metastases, that were treated with OXA or OXA plus Curcumin or vehicle (DMSO) for 24 h. This evidence concerns the gene CXCL1 and colorectal carcinoma.